Yotai Refractories Co., Ltd. (JP:5357) has released an update. Yotai Refractories Co., Ltd. has announced its decision to ...

Cash and Cash Equivalents: As of September 30, 2024, Senti Bio held cash and cash equivalents of $10.5 million. Subsequent to quarter-end, the Company received $2.5 million, the second tranche of an ...

NILACHAL REFRACTORIES LTD. - Board Meeting Intimation for Board Meeting Is Scheduled To Declared 2Nd Quarter For Financial 2024-25.

Please find enclosed herewith extract of statement of Unaudited Consolidated Financial Results for the quarter and six months 30th September, 2024 published in newspapers, Business Standard -All ...

WESTLAKE VILLAGE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter ...

Currently Corvus is enrolling patients in a registrational Phase 3 trial to evaluate soquelitinib to treat refractory ...

Allogene is ceasing enrollment in a Phase I trial of cema-cel for patients with relapsed or refractory chronic lymphocytic ...

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced positive topline results from the relapsed or ...

Last month, a second phase 3 blow for Marinus Pharmaceuticals prompted the Pennsylvania-based drugmaker to turn an eye toward ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Eric Easom, the company's co-founder, chairman, president and chief executive officer, said recent data analysis indicate that epetraborole may provide clinical improvement in patients with ...